PGNX - Progenics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.43
-0.21 (-3.72%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.64
Open5.64
Bid0.00 x 4000
Ask6.48 x 1300
Day's Range5.32 - 5.64
52 Week Range3.62 - 9.42
Volume567,934
Avg. Volume816,887
Market Cap469.014M
Beta (3Y Monthly)2.60
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire4 days ago

    Progenics Announces Preliminary Voting Results of Annual Meeting of Shareholders

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that, based on the preliminary voting results of its 2019 Annual Meeting of Shareholders, Progenics directors Mark R. Baker, Bradley L. Campbell, Karen J. Ferrante, David A. Scheinberg and Nicole S. Williams received a majority of the votes cast at the Annual Meeting, and Peter J. Crowley and Michael D. Kishbauch did not. In accordance with Progenics’ bylaws, Mr. Crowley and Mr. Kishbauch have each submitted a contingent resignation which will become effective only if the certification of the votes of the Annual Meeting confirms that they did not receive a majority of the votes cast and the Board of Directors accepts the resignation.  As required under the Company’s bylaws, the Nominating and Corporate Governance Committee is considering these matters and will recommend to the Board the action to be taken with respect to the tendered contingent resignations.  The Board will determine whether to accept such resignations, or what other action should be taken, in accordance with Progenics’ bylaws.

  • GlobeNewswire8 days ago

    Progenics Urges Shareholders to Vote Today “FOR” the Highly Qualified Director Candidates on the WHITE Proxy Card

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, encourages all shareholders to vote today “FOR” all of the Board’s highly qualified and engaged nominees online or by telephone by following the easy instructions on the “WHITE” Proxy Card. It is imperative that shareholders vote as soon as possible. All shareholders’ votes are extremely important, no matter how many shares they own.

  • PR Newswire8 days ago

    Velan Reminds Stockholders to Follow ISS' Recommendation by Voting "Against" Progenics Pharmaceuticals Directors Peter Crowley and Michael Kishbauch

    Agrees with ISS that "Board Level Change is Warranted, With the Ultimate Goal of Enhancing Shareholder Board Oversight" Urges Stockholders to Vote Before Thursday, July 11 Annual Meeting ALPHARETTA, ...

  • GlobeNewswire8 days ago

    Progenics Pharmaceuticals Strengthens Management Team with Appointment of Huw Jones as Vice President, Commercial

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced the appointment of Huw Jones to the newly created role of Vice President, Commercial. Mr. Jones has over 30 years of global experience leading commercial strategy and operations in the pharmaceutical industry, including almost two decades at Novartis Pharmaceuticals and its subsidiaries, most recently at Advanced Accelerator Applications SA and Novartis Oncology, Ltd. “We are pleased to welcome Huw to our growing commercial operations team to support Progenics’ maturing portfolio of innovative radiopharmaceuticals for the detection and treatment of cancer.

  • PR Newswire15 days ago

    Velan Urges Stockholders To Follow ISS' Recommendation By Voting "Against" Progenics Pharmaceuticals Directors Peter Crowley And Michael Kishbauch

    ALPHARETTA, Ga., July 1, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today issued a statement reminding stockholders that now is the time to demand accountability at Progenics and to follow the recommendation of Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm, by voting AGAINST the election of Progenics directors Peter Crowley and Michael Kishbauch at the Company's upcoming Annual Meeting of Stockholders scheduled to be held on July 11, 2019 (the "Annual Meeting"). In its report, ISS endorsed our call for change on the Progenics Board of Directors (the "Board"), highlighting the Board's seeming unwillingness to recognize the underperformance of the Company under its guidance and noting the Board's failure to hold management accountable for numerous operational and strategic missteps.

  • GlobeNewswire15 days ago

    Leading Independent Proxy Advisory Firm Glass Lewis Recommends Progenics Shareholders Vote “FOR” ALL of Progenics’ Director Nominees

    Glass Lewis Believes Velan’s “Fundamental Operational and Corporate Governance Case Fails to Bear Fruit” Glass Lewis Agrees the Current Settlement Offer is Fair and “Would.

  • PR Newswire18 days ago

    ISS Supports Velan's Call for Change by Recommending Stockholders Vote "Against" Progenics Pharmaceuticals Directors Peter Crowley and Michael Kishbauch

    ISS Believes Velan Presented a "Compelling Argument that Board Level Change is Warranted" to Enhance "Shareholder Board Oversight" ISS Highlights the Board's "Apparent Lack of ...

  • GlobeNewswire18 days ago

    Progenics Reiterates Targeted Directors’ Indispensable Experience and Leadership Critical to the Company’s Long-Term Success

    While we disagree with ISS’ conclusions, we are pleased that ISS recognizes the progress Progenics has made under the oversight of the Board. ISS recommends that shareholders vote FOR CEO Mark Baker, arguing that “the dissident [Velan]…has not presented a sufficient case for an immediate CEO change” and therefore recommends shareholders vote on management’s WHITE proxy card.

  • PR Newswire18 days ago

    Velan Clarifies Interactions with Progenics Pharmaceuticals' Board of Directors

    ALPHARETTA, Ga., June 28, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today responded to more misleading statements by the Progenics Board of Directors (the "Board") regarding recent settlement discussions. The Board's attempts to distort the truth and avoid accountability at all costs continue to prove that its only defense is distraction and misdirection.

  • GlobeNewswire18 days ago

    Progenics Pharmaceuticals Details Recent Good Faith Efforts to Settle with Velan Capital

    Velan Rebuffed Very Reasonable Offer that Included a One Year Standstill, Designating Two New Independent Directors and an Incumbent Director Not Standing for Re-election in.

  • GlobeNewswire21 days ago

    Data Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting Highlights Potential of Progenics’ PSMA-Targeted Imaging Agent, PyL, in Detecting Prostate Cancer

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that results from studies highlighting the PSMA-targeted imaging agent, PyL, were presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting. “The data presented at SNMMI underscore the power of PyL to accurately detect prostate cancer, including high risk and biochemically recurrent disease where more precise imaging can change treatment decisions,” stated Asha Das, M.D., Chief Medical Officer of Progenics.

  • PR Newswire21 days ago

    Velan Releases Presentation Reiterating the Facts and Setting The Record Straight for Progenics Pharmaceuticals' Stockholders

    Highlights How the Board is Distorting the Truth, Mischaracterizing the Company's Current Dire State and Misleading Stockholders in an Attempt to Preserve the Troubling Status Quo Reminds Stockholders ...

  • GlobeNewswire22 days ago

    Independent Readers Using Progenics’ PSMA AI Demonstrated a Statistically Significant Improvement of Accuracy, Speed, and Reproducibility Over Readers Without PSMA AI

    NEW YORK, June 24, 2019 -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find,.

  • GlobeNewswire22 days ago

    Progenics Pharmaceuticals Files Supplemental Investor Presentation Rebutting Velan’s Latest Inaccurate Claims

    Progenics Pharmaceuticals, Inc. (PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today filed a presentation with the U.S. Securities and Exchange Commission (“SEC”) in connection with its upcoming 2019 Annual Meeting (“Annual Meeting”) scheduled for July 11, 2019. The presentation addresses Velan Capital, L.P.’s (“Velan”) latest flawed arguments and is intended to supplement the investor presentation Progenics filed with the SEC on June 21, 2019 detailing the Company’s historic and ongoing actions to enhance shareholder value.

  • PR Newswire26 days ago

    Velan Releases Detailed Presentation on Progenics Pharmaceuticals

    Details the Persistent Performance, Execution, Governance and Transparency Shortcomings that Have Led to the Destruction of Significant Value Highlights the Need for True Accountability in the Boardroom ...

  • GlobeNewswire26 days ago

    Progenics Pharmaceuticals to Initiate a Basket Trial by Year End to Support an Expanded Label for AZEDRA® (iobenguane I 131) in Multiple MIBG Avid Neuroendocrine Tumors

    Progenics Pharmaceuticals, Inc. (PGNX), (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that the Company has reached alignment with the U.S. Food and Drug Administration (FDA) on the clinical development plan to pursue a tissue agnostic indication to support an expanded label for AZEDRA (iobenguane I 131) for the treatment of patients with unresectable or metastatic neuroendocrine tumors (NETs) who are MIBG avid. Following a Type B meeting with the FDA, the Company plans to conduct a basket study that will evaluate AZEDRA in patients with NETs that are MIBG avid, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and other NETs, with a dosing regimen that potentially enables outpatient administration.

  • PR Newswire26 days ago

    Velan Calls on Progenics Pharmaceuticals' Board to Back Up Recent Claims

    ALPHARETTA, Ga., June 20, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today issued the following statement responding to the latest letter from Progenics' Board of Directors (the "Board") to stockholders. Velan calls on the Board to back up its claims by answering a few simple questions.  Progenics stockholders, the true owners of the Company, deserve answers and clarity.

  • GlobeNewswire27 days ago

    Progenics to Mail Letter to Shareholders

    Progenics Pharmaceuticals, Inc. (PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, is mailing a letter to shareholders in connection with its upcoming 2019 Annual Meeting (“Annual Meeting”) scheduled for July 11, 2019. Shareholders of record as of the close of business on May 13, 2019 are eligible to vote at the Annual Meeting.

  • GlobeNewswire28 days ago

    Progenics Pharmaceuticals Announces Agreement with FUJIFILM Toyama Chemical Co. for Automated Bone Scan Index (aBSI) Product in Japan

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight, and follow cancer, today announced that EXINI, a wholly owned subsidiary of Progenics, has entered into a transfer agreement with FUJIFILM Toyama Chemical Co, Ltd. (FFTC) for the rights to Progenics’ Automated Bone Scan Index (aBSI) product in Japan for use under the name BONENAVI.

  • PR Newswire29 days ago

    Velan sets the Record Straight on Progenics Pharmaceuticals' Latest Misleading Statements

    Implores Stockholders to Follow Velan, a True "Fellow Shareholder," and Vote the GREEN Proxy Card Today AGAINST the Re-Election of Messrs. ALPHARETTA, Ga., June 17, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today issued the following statement responding to certain misleading claims made by the Progenics Board of Directors (the "Board").

  • GlobeNewswirelast month

    Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study of 1095 Radiotherapy for the Treatment of Metastatic Prostate Cancer

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that the first patient has been dosed in the Company’s Phase 2 clinical study evaluating I-131 1095 radiotherapy in combination with enzalutamide for the treatment of metastatic castration resistant prostate cancer (mCRPC). 1095 is the Company’s small molecule radiotherapeutic designed to selectively bind to the extracellular domain of prostate specific membrane antigen (PSMA).

  • PR Newswirelast month

    Velan Capital Sends Letter to Stockholders Calling Out Progenics Pharmaceuticals' Board for Unnecessarily Diluting Stockholders to Support Outsized And Undeserved Compensation

    Oops, They Did it Again - Last Week the Board Chose to Further Dilute Stockholders, Proving Toxic Misalignment of Interests Sets the Record Straight on the Board's Misleading Statements Reminds Stockholders ...

  • GlobeNewswirelast month

    Progenics Pharmaceuticals Announces Presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting

    NEW YORK, June 06, 2019 -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find,.

  • PR Newswirelast month

    Velan Responds to Progenics Pharmaceuticals' Misleading Statements

    Implores Stockholders to Follow Velan, a True "Fellow Shareholder" and Vote the GREEN Proxy Card Today AGAINST the re-election of Messrs. On June 3, 2019, the Progenics Board of Directors (the "Board") delivered a letter to "fellow shareholder[s]" touting a commitment "to enhancing the value of [their] investment" yet the non-executive directors collectively own only ~0.06% of Progenics common stock with Peter Crowley and Michael Kishbauch owning ZERO shares of Progenics common stock.i It seems apparent to us that with so little 'skin in the game' and not enough confidence in the Company to engage in meaningful stock purchases, the Board does not have the same commitment to stockholder value as we do.